Cryoport Reports Q3 2026 Revenue Growth Driven by Cell and Gene Therapy Expansion
Cryoport (CYRX) reported third-quarter 2026 revenue of $50.2 million, marking a 14% year-over-year increase. The growth was primarily fueled by an 18% rise in Life Sciences Services revenue and strong demand within the cell and gene therapy sector, which saw commercial therapy revenue grow by 20%. Adjusted EBITDA improved to $1.1 million, up $1.8 million from the previous year as the company moves closer to sustained profitability. Despite some delays in clinical pipeline applications being pushed into 2027, management raised full-year 2026 revenue guidance to a range of $197 million to $199 million. The company maintains a strong liquidity position with $393.1 million in cash and short-term investments, supporting ongoing global supply chain infrastructure investments and network expansion.
Topics: cell and gene therapy EBITDA improvement guidance raise revenue growth